Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2024-09-30 00:00:00 ET · period of report 2024-09-27 · accession 0000950170-24-110485 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 2024-09-27 | VRDN | Beetham Thomas W. | COO | P - Purchase | $23.41 | +5,000 | 6,000 | +500% | +$117.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-27 | P | A | 5,000 | $23.41 | 6,000 | D | — | — | (F1) Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on September 19, 2024 in transactions that were exempt under Rule 16b-3(c). |